ICCC IMMUCELL CORP /DE/

Nasdaq immucell.com


$ 6.03 $ -0.19 (-3.04 %)    

Friday, 17-Oct-2025 14:40:32 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 6.06
$ 6.35
$ 5.84 x 600
$ 6.70 x 24
$ 6.06 - $ 6.35
$ 3.38 - $ 7.60
8,929
na
54.73M
$ 0.07
$ 31.07
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-28-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 04-01-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-29-2023 12-31-2022 10-K
12 11-21-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-30-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-30-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-12-2020 06-30-2020 10-Q
22 05-13-2020 03-31-2020 10-Q
23 03-27-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-12-2019 06-30-2019 10-Q
26 05-13-2019 03-31-2019 10-Q
27 03-22-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-13-2018 06-30-2018 10-Q
30 05-14-2018 03-31-2018 10-Q
31 03-29-2018 12-31-2017 10-K
32 11-13-2017 09-30-2017 10-Q
33 08-14-2017 06-30-2017 10-Q
34 05-11-2017 03-31-2017 10-Q
35 03-30-2017 12-31-2016 10-K
36 11-10-2016 09-30-2016 10-Q
37 08-11-2016 06-30-2016 10-Q
38 05-11-2016 03-31-2016 10-Q
39 03-25-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 immucell-announces-preliminary-q3-2025-revenue-of-55m

ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develop...

 immucell-selects-olivier-te-boekhorst-as-its-next-president-ceo-expected-start-date-november-1-2025

PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company...

 immucell-q2-eps-006-up-from-020-yoy-sales-6445m-up-from-5473m-yoy

ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.06 per share. This is a 130 percent increase over losses of $(0.20) pe...

 immucell-preliminary-q1-2025-revenue-of-81m-up-from-73m-yoy-reduced-the-backlog-of-orders-to-4m-as-of-march-31-2025-from-44m-as-of-december-31-2024

- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that devel...

 immucell-q4-eps-006-up-from-015-yoy-sales-775m-up-from-510m-yoy

ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.06 per share. This is a 140 percent increase over losses of $(0.15) pe...

 immucell-settles-insurance-claim-for-426k-covering-production-contamination-losses-adding-to-250k-paid-in-q3-2023

ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develop...

 reported-earlier-immucell-preliminary-q4-sales-of-78m-52-yoy-and-fiscal-2024-of-265m-52-yoy-driven-by-increased-production

Preliminary, Unaudited Total Sales Results: 20242023$ Increase% Increase During the Three-Month Periods Ended December 31,$7.8 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION